[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.166.22. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1990

Sulfasalazine as Folic Acid Inhibitor in Psoriasis-Reply

Author Affiliations

Department of Dermatology University of Michigan Medical Center 1910 Taubman Center, Box 0314 1500 E Medical Center Dr Ann Arbor, MI 48109-0314

Arch Dermatol. 1990;126(11):1516-1517. doi:10.1001/archderm.1990.01670350132026

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

In Reply.—  We thank Hallasz for his interesting comments. In our study, comparing the group of patients receiving sulfasalazine with those receiving placebo, there was no significant difference in the mean corpuscular volume of red blood cells after 4 weeks of sulfasalazine therapy (by which time signs of significant clinical improvement of psoriasis had usually occurred). We agree that the possibility that sulfasalazine may be beneficial in psoriasis treatment by acting as a folate inhibitor needs to be pursued and future studies should incorporate more specific tests, including serum folate levels (and better still, red blood cell folate levels). Such studies would need to monitor other factors that may affect tissue folate stores, including drug and dietary intake, presence of diseases that may affect folate metabolism, and hemolysis due to other causes.Sulfasalazine does not exhibit the dose-dependent toxic effects of bone marrow suppression and gastrointestinal ulceration that methotrexate can. Therefore, sulfasalazine

First Page Preview View Large
First page PDF preview
First page PDF preview
×